Mangalam Drugs and Organics Ltd. CMP :175.45, BOOK VALUE: 48.48, PE : 11.72,FACE VALUE : 10 DEBT TO EQUITY RATIO : 1.13
Promoters stake increasing,reducing debt,year on year sales increasing.
Mangalam Drugs & Organics Limited commenced in 1977 its manufacturing of Active Pharmaceutical Ingredients APIs, Intermediates at VAPI – Gujarat. It has a multi-product manufacturing facility on two locations, and an in-house R&D.
Over last three decades, the company has acquired worldwide reputation as a single stop destination for frontline Antimalarials.
Company is focused at present in the manufacturing of the following:
Active Pharma Ingredients (API)
Company has a diversified product range having synergies in operations and economies of scale. It is amongst the top manufacturers in Asia in all the products it manufactures, and is a largest manufacture of some of its products in the world.
It has the WHO-GENEVA GMP Certification and EDQM approval for its API manufacturing plant. The company is also certified ISO 9001:2008 by DNV for design, development, manufacture and supply of API and Intermediates.
Company has also sign an agreement with the prestigious Clinton Health Access Initiatives (CHAI) under its Fight Malaria Program for supply of anti malarial API worldwide.
RESEARCH & DEVELOPMENT
R & D Lab Approved By DSIR: Department of Scientific & Industrial Research, Delhi Govt of India.
R & D’s 33 scientists make Mangalam’s most proactive and market responsive team. The team has an excellent blend of dynamic post graduates who are on one hand productive at the bench and are simultaneously capable to address any formidable synthetic or analytical challenge on the other.
The department’s interventions in the processing chain span from the performance testing and validation of price competitive raw materiel to the optimization of processes to meet most stringent stability and quality requirements. However simple may be the process-change; the piloting of a lab process is considered a prerequisite to learn safety and mass transfer issues which may become major technology transfer hurdles while scaling up.
Dedicated pilot plant and analytical services facility work in close association with R & D. R & D is a ‘game changer’. At present we have 7 ARVs, 2 anti TB, 1 anti malaria and 1 other development candidates populating the pipeline.
WE ARE EXPECTING GOOD RETURNS FROM CMP 175.45 FOR LONG TERM.INVEST ONLY Rs.2000/- TO 3000/-. DON’T INVEST YOUR 100% CAPITAL IN ONE STOCK.
This site has been designed for informational and educational purposes only. The services and information provided through this site are for personal, non-commercial, educational use and display. I am not Certified Advisor we donot ask OR force to take market positions in any particular Stock,Future and Options.All are our personal views.Before trade or invest consult certified advisor.